Laigo Bio

Oncode Institute and Argobio launch Laigo Bio, a targeted membrane protein degradation biotech in oncology and neurological disorders


  • Scientific founder : Prof. Madelon Maurice, researcher and group leader at UMC Utrecht
  • The primary focus lies in the area of oncology, but with parallel programs in neuro-inflammation and neuro degenerative diseases
  • Argobio and the Oncode Institute will support the company's development to Series A financing
  • Additionally secured funding from Oncode Bridge Fund
  • Laigo Bio is gearing up for preclinical lead development in the coming months
  • Collaborative ecosystem

Madelon Maurice
Scientific founder

Our latest news